Enasidenib

Ivosidenib or enasidenib in combination with chemotherapy showed promising safety and efficacy profiles for newly diagnosed IDH-mutated acute myeloid leukemia, according to a phase 1 trial presented at ASH Annual Meeting and Exposition.

In this video, Farhad Ravandi, MD, reviews recent advances in acute myeloid leukemia therapies discussed at the Society of Hematologic Oncology Annual Meeting.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the transition of newer agents into clinical practice.

Healio spoke with Ajay K. Nooka, MD, MPH, FACP, associate professor of hematology and medical oncology at Emory School of Medicine, about exciting progress in anti-BCMA targeted therapies and products in the pipeline.

A randomized phase 3 trial designed to evaluate the addition of enasidenib to best supportive care for certain patients with acute myeloid leukemia failed to meet its primary endpoint, according to the agent’s manufacturer.